Health and Healthcare

Alkermes : ALKS

All Alkermes Articles

93 Articles

Chris Lange | Jul 15, 2019 at 9:55 AM EDT

Alkermes Looks to Expand Its Schizophrenia Treatment to Bipolar Patients

Alkermes shares made a handy gain on Monday after the firm announced that it would be expanding its New Drug…

Jon C. Ogg | Jul 15, 2019 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: Agilent, Amazon, American Water Works, Crocs, Deere, GE, Gilead, Slack, Teva and More

The top analyst upgrades, downgrades and initiations on Monday included Agilent Technologies, Amazon.com, American Water Works, Crocs, Deere, General Electric,…

Jon C. Ogg | May 31, 2019 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: Alkermes, Apple, Canada Goose, FireEye, J.Jill, Kraft Heinz, Uber, Vonage and More

The top analyst upgrades, downgrades and initiations seen on Friday included Alkermes, Apple, Canada Goose, FireEye, J.Jill, Kraft Heinz, Uber…

Jon C. Ogg | May 1, 2019 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: Alkermes, Alphabet, Apple, Conoco, FireEye, Lyft, McDonald’s, RBS, Seagate, Shopify and More

The top analyst upgrades, downgrades and initiations seen on Wednesday included Alkermes, Alphabet, Apple, ConocoPhillips, FireEye, Lyft, McDonald's, Royal Bank…

Jon C. Ogg | Dec 19, 2018 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: Apple, Baker Hughes, Biogen, FedEx, Intel, Micron, Roku, Shake Shack and More

The top analyst upgrades, downgrades and initiations seen on Wednesday included Apple, Baker Hughes, Biogen, FedEx, Intel, Micron Technology, Roku…

Chris Lange | Nov 2, 2018 at 9:19 AM EDT

Why the FDA Is Dragging Alkermes Down

Alkermes shares dropped early on Friday after the company anncounced the results from its most recent meeting with the U.S.…

Jon C. Ogg | Aug 7, 2018 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts, Zillow and More

The top analyst upgrades, downgrades and other research calls from Tuesday include Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts…

Lee Jackson | Jun 6, 2018 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: Alkermes, Cigna, International Paper, Medtronic, Tesla, Western Digital and More

The top analyst upgrades, downgrades and other research calls from Wednesday include Alkermes, Cigna, International Paper, Medtronic, Tesla and Western…

Lee Jackson | May 11, 2018 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp, Sarepta Therapeutics and More

The top analyst upgrades, downgrades and other research calls from Friday included AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp…

Chris Lange | Apr 16, 2018 at 9:55 AM EDT

Alkermes Wins Big on FDA Approval

Shares of Alkermes saw a handy gain to start out the week after the FDA made a critical decision about…

Chris Lange | Apr 2, 2018 at 9:40 AM EDT

FDA Gets Down on Alkermes Depression Drug

Alkermes saw its shares drop early on Monday after the company announced that it received a Refusal to File letter…

Jon C. Ogg | Feb 22, 2018 at 9:14 AM EST

Top Analyst Upgrades and Downgrades: Alkermes, ArQule, Bluebird Bio, Cognizant, Ecolab, KLA-Tencor, Pandora, Verisk, Vonage and More

The top analyst upgrades, downgrades and other research calls from Thursday include Alkermes, ArQule, Bluebird Bio, Cognizant Technology Solutions, Ecolab,…

Chris Lange | Jan 6, 2018 at 8:55 AM EST

20 More Biopharma Catalysts Coming in 2018

Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves…

Chris Lange | Nov 27, 2017 at 10:05 AM EST

Alkermes Could Win Big With New Biogen Partnership

Alkermes saw its shares make a handy gain to start off the week, after the firm announced that it has…

Jon C. Ogg | Oct 16, 2017 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Adobe, Apple, Bristol-Myers, Citigroup, Ford, Groupon, Phillips 66, United Rentals and More

The top analyst upgrades, downgrades and other research calls from Monday include Adobe, Apple, Bristol-Myers, Citigroup, Ford, Groupon, Phillips 66…

1 2 3 4 … 7

Alkermes : ALKS

All Alkermes Articles

Alkermes Looks to Expand Its Schizophrenia Treatment to Bipolar Patients

Top Analyst Upgrades and Downgrades: Agilent, Amazon, American Water Works, Crocs, Deere, GE, Gilead, Slack, Teva and More

Top Analyst Upgrades and Downgrades: Alkermes, Apple, Canada Goose, FireEye, J.Jill, Kraft Heinz, Uber, Vonage and More

Top Analyst Upgrades and Downgrades: Alkermes, Alphabet, Apple, Conoco, FireEye, Lyft, McDonald’s, RBS, Seagate, Shopify and More

Top Analyst Upgrades and Downgrades: Apple, Baker Hughes, Biogen, FedEx, Intel, Micron, Roku, Shake Shack and More

Why the FDA Is Dragging Alkermes Down

Top Analyst Upgrades and Downgrades: Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts, Zillow and More

Top Analyst Upgrades and Downgrades: Alkermes, Cigna, International Paper, Medtronic, Tesla, Western Digital and More

Top Analyst Upgrades and Downgrades: AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp, Sarepta Therapeutics and More

Alkermes Wins Big on FDA Approval

FDA Gets Down on Alkermes Depression Drug

Top Analyst Upgrades and Downgrades: Alkermes, ArQule, Bluebird Bio, Cognizant, Ecolab, KLA-Tencor, Pandora, Verisk, Vonage and More

20 More Biopharma Catalysts Coming in 2018

Alkermes Could Win Big With New Biogen Partnership

Top Analyst Upgrades and Downgrades: Adobe, Apple, Bristol-Myers, Citigroup, Ford, Groupon, Phillips 66, United Rentals and More

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Warren Buffett’s Parting Gift to Investors Is Crushing the Market 6 Months Later

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

College-Educated Families Earned $242,200 While Others Made $42,200, Here's Why the Gap Widened

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Alkermes : ALKS

All Alkermes Articles

Alkermes Looks to Expand Its Schizophrenia Treatment to Bipolar Patients

Top Analyst Upgrades and Downgrades: Agilent, Amazon, American Water Works, Crocs, Deere, GE, Gilead, Slack, Teva and More

Top Analyst Upgrades and Downgrades: Alkermes, Apple, Canada Goose, FireEye, J.Jill, Kraft Heinz, Uber, Vonage and More

Top Analyst Upgrades and Downgrades: Alkermes, Alphabet, Apple, Conoco, FireEye, Lyft, McDonald’s, RBS, Seagate, Shopify and More

Top Analyst Upgrades and Downgrades: Apple, Baker Hughes, Biogen, FedEx, Intel, Micron, Roku, Shake Shack and More

Why the FDA Is Dragging Alkermes Down

Top Analyst Upgrades and Downgrades: Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts, Zillow and More

Top Analyst Upgrades and Downgrades: Alkermes, Cigna, International Paper, Medtronic, Tesla, Western Digital and More

Top Analyst Upgrades and Downgrades: AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp, Sarepta Therapeutics and More

Alkermes Wins Big on FDA Approval

FDA Gets Down on Alkermes Depression Drug

Top Analyst Upgrades and Downgrades: Alkermes, ArQule, Bluebird Bio, Cognizant, Ecolab, KLA-Tencor, Pandora, Verisk, Vonage and More

20 More Biopharma Catalysts Coming in 2018

Alkermes Could Win Big With New Biogen Partnership

Top Analyst Upgrades and Downgrades: Adobe, Apple, Bristol-Myers, Citigroup, Ford, Groupon, Phillips 66, United Rentals and More

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Warren Buffett’s Parting Gift to Investors Is Crushing the Market 6 Months Later

Featured Reads

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

College-Educated Families Earned $242,200 While Others Made $42,200, Here's Why the Gap Widened